EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Borenstein, N.
Right arrow Articles by Montarras, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Borenstein, N.
Right arrow Articles by Montarras, D.
Related Collections
Right arrow Cardiac - other
Right arrow Congestive Heart Failure

Eur J Cardiothorac Surg 2007;31:444-451. doi:10.1016/j.ejcts.2006.12.023
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Non-cultured cell transplantation in an ovine model of non-ischemic heart failure

Nicolas Borenstein*, Valérie Chetboul, Patrick Bruneval, Mehrak Hekmati, Renaud Tissier, Luc Behr, Geneviève Derumeaux, Didier Montarras

IMM Recherche, 42 bd Jourdan, 75014 Paris, France

Received 26 May 2006; received in revised form 30 November 2006; accepted 4 December 2006.

* Corresponding author. Tel.: +33 1 56 61 68 21; fax: +33 1 56 61 67 40. (Email: nicolas.borenstein{at}imm.fr).

Objective: Cell therapy may be a promising alternative or adjunct to current treatment modalities for ischemic heart failure. But little is known on the impact of myogenic cell transplantation in large animal models of non-ischemic cardiomyopathy. The aim of the present study was to explore whether an ovine model of toxin-induced heart disease could benefit from non-cultured skeletal muscle cell transplantation. Methods: Sequential intracoronary injections of doxorubicin (0.75 mg/kg) were carried out every 2 weeks until echocardiographic detection of myocardial dysfunction. Sheep were then randomly assigned to either non-cultured cell transplantation (n = 8) or placebo injection (n = 5). For the cell therapy group, a skeletal muscle biopsy (about 10 g) was explanted from each animal approximately 3 h before grafting. After thoracotomy, 20 epicardial injections were carried out. The animals were assessed one last time before sacrifice, 2 months after the thoracotomy. Cells were tracked with cmDiI (red fluorescence) and characterized with immunohistochemistry with monoclonal antibodies to a fast skeletal isoform of myosin heavy chain. Results: Two months after intramyocardial grafting, tissue Doppler imaging and conventional echocardiographic assessment of the groups showed a marked improvement in the non-cultured cell therapy group. Ejection fraction (EF) (p < 0.05) as well as systolic endocardial velocities (p < 0.01) improved versus the placebo group. CmDiI and skeletal myosin heavy chain expression was detected in all animals at 2 months after implantation confirming engraftment of skeletal muscle cells. Conclusions: In conclusion, our data indicate that non-cultured muscle cell transplantation is feasible and may translate into a functional benefit in an ovine model of dilated heart failure.

Key Words: Cell transplantation • Cell culture • Satellite cells • Cardiomyopathy • Heart failure






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.